Kornimate/medical-research-clean huggingface dataset:
comparative evaluation of two prf formulations on quality of life and healing of apicomarginal defects

Conditions: Apico Marginal Defects

Summary: healing of apicomarginal defects using 2 different formulations of prf i.e prf -high and prf-medium will be assessed and compared using 2d and 3d criteria. also, in vitro evaluation of the prf formulations and quality of life will be compared between the two groups.

periapical surgery is a viable treatment option in teeth with persistent apical periodontitis, especially in cases which fail to heal by non surgical treatment. kim and kratchman classified periradicular lesions into categories a-f. lesions a-c are of endodontic origin without any periodontal pockets and vary with respect to the size of periapical radiolucency while d-f are combined endodontic - periodontal origin and are ranked accoding to the magnitude of periodontal breakdown. type f defects are commonly referred to as apicomarginal defects and have worst prognosis among all. the lower success rate is attributed to the apical migration of junctional epithelium and intrusion of non osteogenic connective tissue into the periapical region. recently, autologous platelet concentrates have been used instead of the conventional practice of using gtr barrier membranes for treating apicomarginal defects. till date no human study has compared platelet formulations; prf-high ( 2700 rpm for 12minutes) and prf-medium (1500 rpm for 14minutes) to see any difference in the bony healing and the quality of life between the two groups and no study have assessed bony healing of the periapical defect with periodontal communication with the use of cbct. thus, the aim of the present study is to investigate the effect of 2 different formulations of prf on quality of life and healing outcome of periapical defects with periodontal communications . also, in vitro histological and immunohistochemical evaluation and comparison of the clots prepared from different centrifugation protocols will be done .

Eligibility criteria:
inclusion criteria: 1. patients of age 16 years and above. 2. patients with no general medical contraindications for oral surgical procedures (asa-i and asa-ii according to the classification of the american society of anesthesiologist's. 3. periapical defect with periodontal communication. 4. periodontal pocket \>6mm with apicomarginal communication confined to buccal aspect of interproximal space or mid buccal aspect of the root. 5. negative response to vitality test. 6. failed previous root canal treatment with purulent discharge or failed previous surgery or recurrent episode of purulent discharge. exclusion criteria: 1. presence of buccal bone on flap elevation. 2. unrestorable tooth. 3. fractured /perforated roots. 4. smokers. 5. pregnant females and lactating mothers
comparative study on pharmacokinetics of two formulations of jaktinib in healthy adults under fasting conditions

Conditions: Myelofibrosis

Summary: to evaluate the pharmacokinetic characteristics of two formulations of jaktinib hydrochloride tablets in healthy adult volunteers


Eligibility criteria:
inclusion criteria: * 18≤ age ≤ 45, male or female; * body weight: ≥50 kg for male, ≥45 kg for female; body mass index (bmi): 19.0-26.0 kg/m\^2 (inclusive); * informed consent will be signed before the trial, and the content, process and possible adverse reactions of the trial will be fully understood; * the volunteers should be able to communicate well with the researchers and understand and comply with the requirements of the study. exclusion criteria: * participants who were enrolled in a clinical trial or used a study drug within 3 months before administration of the study drug; * participants with chronic or active gastrointestinal diseases such as esophageal disease, gastritis, gastric ulcer, enteritis, active gastrointestinal bleeding, or gastrointestinal surgery within the past three years and still clinically relevant according to the investigator; * participants with definite diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, metabolic system and other diseases that require medical intervention or are not suitable for clinical trial (such as psychiatric history); * with positive alcohol breath test; * volunteers may not be able to complete the study for other reasons or have other reasons for not participating in the study as judged by the investigator.
a study to compare the efficacy and safety of a combination of ketoconazole and clindamycin compared to tetracycline/amphotericin b combination cream for the treatment of bacterial vaginosis and vaginal candidiasis (p08077)

Conditions: Vaginosis, Bacterial; Candidiasis, Vulvovaginal

Summary: this is a study to compare the safety and efficacy of the use of a intravaginal ovule containing a combination of ketoconazole and clindamycin to the use of an intravaginal cream containing a combination tetracycline and amphotericin b for the treatment of bacterial vaginosis and/or mixed or isolated vaginal candidiasis.


Eligibility criteria:
inclusion criteria: * diagnosis of vaginal candidiasis * no trichomonas vaginalis or any other protozoa * no clinical evidences of infection by neisseria gonorrhoeae, chlamydia trachomatis, or viral infections exclusion criteria: * known sensitivity to the formula components * pregnant or nursing patients * any gynecological condition contraindicating the use of vaginal ovule or cream. * use of any other local or systemic bactericidal, anti-protozoa or antifungal agent within the 2 weeks prior to the study start or during it * presence of other sexually transmitted diseases (except from candidal vaginitis). * history of recurrent candidiasis (≥4 episodes per year) * use of intra-uterine device, spermicides, or diaphragms * has metabolic or immune disorder * has abnormal uterine bleeding
effects of xal-ease on patient compliance with xalatan

Conditions: Glaucoma

Summary: the study hypothesis is that the xal-ease with increase patient compliance with xalatan


Eligibility criteria:
inclusion criteria: * 40 to 80 years old * diagnosis warranting treatment with xalatan eye drops. * ambulatory and well functioning exclusion criteria: * non-ambulatory * less than 40 or greater than 80 years old * not using xalatan eye drops

Keywords: glaucoma compliance eye drops deliver aid patients could range anywhere from 40 to 80 years old patients must have diagnosis requiring treatment with xalatan. patients will be male or female and from any racial/ethnic background.
prediction of fetal macrosomia by us

Conditions: Fetal Macrosomia

Summary: fetal macrosomia defined as birth weight above 90th centile ,macrosomia occurs in 42-62%of pregnancy complicated by type 1 diabetes mellitus ,in 30-56% of pregnancy complicated by type 2 diabetes mellitus . -the delivery of macrosomic infant has potentially severe consequence for both the newborn and mother .increased birth weight increase the risk in the fetus of shoulder dystocia and premature brachial plexus injury ,and those infant weighing above 4500g are at increased risk for neonatal morbidity ,including the need for assisted ventilation and meconium aspiration .maternal complication result from operative delivery and include postpartum hemorrhage ,third or fourth degree laceration and postpartum infection .

estimated fetal body weight is needed especially when head measurement is impossible whenever the fetal head is positioned low in pelvic brim .a convenient method for estimating fetal body weight without head measurement was thus required . -the human placenta develop with the principal function of providing nutrients and oxygen to the fetus ,adequate fetal growth and subsequent normal birth weight depend on normal placenta .

Eligibility criteria:
inclusion criteria: * 1.singleton gestational 2.gestational age over 16-20 weeks 3.intact membrane 4.normal umbilical morphology (two arteries and one vein ) exclusion criteria: 1. the presence of fetal congenital anomaly . 2. multifetal pregnancy. 3. maternal chronic disease (hypertension, renal disease ,and pulmonary disease ,etc.) 4. patient with a diagnosis such as oligohydramnios ,preeclampsia and intrauterine growth retardation . 5. patient who used cigarette or alcohol during pregnancy.
the dual factor model of mental health in inpatients

Conditions: Psychological Disease; Depression

Summary: the dual factor model of mental health (dfm; greensporn \& saklofske, 2001) postulates that mental health consists of two at least partially unrelated factors, the experience or absence of psycho-pathological symptoms (i.e. depressive symptoms) and the experience or absence of positive mental health (i.e. life satisfaction, meaningfulness). both factors contribute to an individual's well-being and mental health.the dfm has been used as a framework to describe and evaluate participants' mental health in different settings in cross-sectional and longitudinal designs mostly outside of clinical settings. psychological interventions, such as cognitive-behavioral therapy are widely studied concerning their reduction of psycho-pathological symptoms. however, little is known about the effect of psychological interventions on the second factor (positive mental health) of the dfm. this is especially important, because the latter has been shown to contribute significantly to subjective well-being and to reduce the risk of suicidal intentions and behavior. primary, the authors aim to investigate the dfm in an inpatient sample over the course of time (pre-treatment, post-treatment, 6 and 12 months after discharge). secondly, they aim to investigate the relationship between positive mental health and suicidal ideation over the course of time.

participants will be divided into four groups according to the dfm over the course of time: 1. unhappy: high psychopathology and low positive mental health; depression and/or anxiety scores above published cut -offs and positive mental health scores under published cut offs. 2. symptomatic but content: high psychopathology and high positive mental health; depression and/or anxiety scores above published cut -offs and normal to high positive mental health scores 3. vulnerable: low psychopathology and low positive mental health; depression and/or anxiety scores under published cut -offs and positive mental health scores under published cut offs 4. complete mental health: low psychopathology and high positive mental health; depression and/or anxiety scores under published cut -offs normal to high positive mental health scores. the authors will then depict the movements of patients through these groups graphically and use regression analyses to check for differences according to age, diagnosis and gender. towards the second aim they will use regression analyses to investigate the protective effect of positive mental health on suicidal ideation or behavior.

Eligibility criteria:
inclusion criteria: -inpatients at the stiilachaus privatklinik exclusion criteria: -none

Keywords: dual factor model positive mental health suicidal ideation
role of physical therapy in relieving constipation in children with spastic cerebral palsy

Conditions: Cerebral Palsy, Spastic

Summary: this study was conducted to determine the effectiveness of physical therapy management in relieving constipation among spastic cerebral palsy children. there were two groups, group a received routine physical therapy and group b received maintenance physical therapy (aim to maintain current level of spasticity, functionality to avoid deterioration of conadition as approved by asrc)

physical therapy makes an integral part of the non-pharmacological, conservative management of cerebral palsy. routine physical therapy aims to reduce spasticity, improve joint range of motion (rom), and improve strength and mobility. passive rom and stretching of lower limb and trunk increases parasympathetic activity and thus improves intestinal motility in prolonged bed ridden patients.abdominal muscle training improves intestinal motility by two ways: mechanically by improving fecal propulsion towards rectum and neurologically by inducing parasympathetic activity to improve intestinal motility.20 thermotherapy of back and abdomen in chronic constipation patient improves intestinal blood flow and parasympathetic activity.

Eligibility criteria:
inclusion criteria: * the inclusion criteria for the recruitment in the study were: spastic cp children on oral feeding with constipation between ages 2-12 years of both genders, spasticity above 1+ grade on modified ashworth scale, functional activity level between 2-5 grades on gross motor functional classification scale (gmfcs). exclusion criteria: * cp children with other systemic co-morbidities, physical deformity in git and intellectual disability were excluded from the study.

Keywords: cerebral palsy spasticity constipation gross motor functional classification scale defecation frequency constipation severity
comparison of sepsis prediction algorithms

Conditions: Sepsis

Summary: sepsis is a severe response to infection resulting in organ dysfunction and often leading to death. more than 1.5 million people get sepsis every year in the u.s., and 270,000 americans die from sepsis annually. delays in the diagnosis of sepsis lead to increased mortality. several clinical decision support algorithms exist for the early identification of sepsis. the research team will compare the performance of three sepsis prediction algorithms to identify the algorithm that is most accurate and clinically actionable. the algorithms will run in the background of the electronic health record (ehr) and the predictions will not be revealed to patients or clinical staff. in this current evaluation study, the algorithms will not affect any part of a patient's care. the algorithms will be deployed across the emory healthcare system on data from all patients presenting to the emergency department.

the primary goal of this study is to prospectively evaluate three sepsis prediction algorithms that are embedded in the ehr. the models will be deployed in a "shadow" mode, and the results will not be displayed to the treatment team during this study. two of the algorithms are proprietary algorithms of the ehr provider (epic). the third algorithm is an internally developed, open-source algorithm. the algorithms will compute the probability of sepsis at periodic intervals and will continue to run on a patient's data until the patient's discharge, death, or upon initiation of intravenous antibiotics (at which point there is an indirect record of clinical suspicion of an infection).

Eligibility criteria:
inclusion criteria: * all adult patients admitted through the ed exclusion criteria: * none

Keywords: infection emergency department algorithm prediction
study of tumor antigen-pulsed autologous dendritic cell vaccination administrated subcutaneously or intranodally

Conditions: Multiple Myeloma

Summary: the purpose of this study is to determine if vaccination with autologous idiotype- or tumor lysate-pulsed dendritic cells induces the generation of anti-idiotypic and anti-tumor immunologic responses.

this is an experimental treatment that will consist of receiving special white blood cell administrations either underneath the skin or in the lymph nodes. in this protocol, treatment will be given according to the "risk group". if there are certain abnormalities in the chromosomes, the disease is considered to be high risk. high-risk patients will first receive one cycle of chemotherapy with a regimen called dt pace, after which the white blood cells will be collected. leukapheresis is a procedure in which blood is removed, white blood cells are saved, and the remaining blood is given back to you. these dendritic cells will then be mixed with your individual myeloma protein and/or cells, and keyhole limpet hemocyanin (klh) that is necessary for the enhancement of immune response against myeloma antigens. it is hoped that this will cause these cells to interact with and activate t cells, which will then destroy myeloma cells in your body. half of these white cells will be injected into your lymph nodes (intranodally) and half will be given subcutaneously. high risk patients will receive a chemotherapy regimen called dt pace.

Eligibility criteria:
inclusion criteria: * patients must have confirmed diagnosis of one of the following: smoldering or indolent multiple myeloma, multiple myeloma more than 1 year after autologous transplant and with stable disease, or multiple myeloma with cytogenetic abnormalities * patients with secretory iga or igg must have purified idiotype protein available and/or tumor cells available, and patients with light chain or non-secretory myeloma must have tumor cells available * karnofsky performance score greater than or equal to 60 * anc greater than or equal to 1,000/microliters, platelet count greater than or equal to 60,000/microliters, and cd4 count greater than or equal to 400/microliters. * expected survival of 3 months or more * 18 years of age and older * have given a written consent and been informed about the investigational nature of the study. * negative serology for hiv, hepatitis c, and negative for hepatitis b surface antigen exclusion criteria: * patients with cd4 count \< 400/microliters, and/or with severely damaged immune functions * chemotherapy or other immunosuppressive treatment with steroids, cytoxan, methotrexate within 8 weeks * fever or active infection * liver function: total bilirubin greater than or equal to 2 x uln or ast/alt greater than or equal to 3 x uln * renal function: patients on dialysis * simultaneous treatment with a second investigational drug or biologic agent

Keywords: multiple myeloma dtpace dexamethasone thalidomide cisplatin cytoxan doxorubicin etoposide dendritic cell vaccination leukapheresis
bioequivalency study of oxymorphone hydrochloride 10 mg tablets under fasted conditions

Conditions: Pain

Summary: the objective of this study was to prove the bioequivalence of oxymorphone hydrochloride 10 mg tablets under fasting conditions


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. treatment with known enzyme altering drugs. history of allergic or adverse response to oxymorphone hydrochloride or any comparable or similar product.
diagnostic and prognostic value of d-lactate and scube-1 levels in critically ill patients

Conditions: Critical Illness; D-Lactate; SCUBE-1

Summary: the investigators aimed to investigate the diagnostic and prognostic levels of d-lactate and scube-1 in critically ill patients being admitted to the emergency department.

patients who were diagnosed according to the criteria as being critically ill by the ed responsible physician (patients whose basic vital functions are unstable, who receive supportive treatment or whose general condition is expected to deteriorate) were included. patients over 18 years of age who agreed to participate in the study were included after consent was obtained from the patient or their relatives. patients who did not meet the definition of critical patients, whose follow-up was incomplete, who did not want to participate in the study, pregnant women, and patients under 18 years of age were all excluded. a healthy control group was formed from the relatives of the patients who came to the ed outpatient clinics, as well as hospital staff who wanted to participate in the study. age, gender, known diseases, medications, vital parameters, and the laboratory results from critically ill patients and healthy volunteers admitted to the ed were recorded, and blood samples taken for d-lactate and scube-1 at the time of admission to the emergency room were placed in ethylenediaminetetraacetic acid (edta) tubes. clinical scores, such as the glasgow coma scale (gcs), acute physiology and chronic health evaluation (apache) ii, revised trauma score (rts), and shock index were calculated. critical patients were divided into the following seven groups according to their emergency department diagnosis: central nervous system, cardiovascular system, respiratory system, gastrointestinal system/metabolic, sepsis, trauma, and other. the clinical outcomes of these patients (ed length of stay, icu or ward admission, ed and icu mortality) were also noted. the relationship between the patient's clinical scoring (gcs, apache ii, rts and shock index ), laboratory results, and mortality status with d-lactate and scube-1 levels was compared. at the same time, the diagnostic value of d-lactate and scube-1 for distinguishing critically ill patients was investigated.

Eligibility criteria:
inclusion criteria: age 18 years or older evaluated as critically ill by emergency department physician exclusion criteria: patients not meeting critical illness criteria patients with incomplete follow-up records patients who declined to participate in the study pregnant women individuals under 18 years of age

Keywords: d-lactate scube-1 critical illness
evaluation of the accuracy of the inratio prothrombin time (pt) monitoring system with a new test strip for the oral anticoagulation therapy patient in the presence of heparin and low molecular weight heparin (e.g., enoxaparin or dalteparin)

Conditions: Coagulation

Summary: this is a multi-center study designed to evaluate the heparin insensitivity of the inratio prothrombin time (pt) monitoring system, utilizing an inratio test strip additionally modified for low sample volume. the inratio test strip is used for the quantitative determination of pt and international normalized ratio (inr) results in fingerstick blood from subjects on oral anticoagulation therapy (oat) with warfarin. this study is designed to evaluate the accuracy of the modified inratio test strip during heparin-warfarin bridge therapy with unfractionated heparin (uh) or low molecular weight heparin (lmwh), such as enoxaparin or dalteparin. these inr results will be compared to the inr results obtained on plasma from the same subjects as analyzed at a central laboratory with the heparin-insensitive reference method: the sysmex ca-560 system. the levels of uh or lmwh in the plasma samples will be assessed using activated partial thromboplastin time (aptt) and anti-factor-xa assays respectively.


Eligibility criteria:
inclusion criteria: * adults (18 years of age or older). * willing and able to provide written informed consent and comply with study procedures. * receiving warfarin/heparin bridge therapy. * therapy with both warfarin and one of the heparins listed below must have been initiated for at least 12 hours before the first study specimens are obtained. * uh (last known aptt prior to enrollment (if available†) must confirm heparin has been administered) * dalteparin (last known anti-factor xa prior to enrollment (if available†) must confirm heparin has been administered) * enoxaparin (last known anti-factor xa prior to enrollment (if available†) must confirm heparin has been administered) † if a pre-study aptt or anti-factor xa is not available, subsequent testing of the study phlebotomy or a phlebotomy as a part of routine medical care taken before or during the time of the study phlebotomy must confirm the presence of heparin (unfractionated or low molecular weight) in order for that data point to be included in the analysis. exclusion criteria * known or suspected hematocrit less than 25 or greater than 55%; * auto-immune disorders known to interfere with inr measurements, such as lupus or anti-phospholipid syndrome (aps) * already participated in this specific study

Keywords: patients needing oat (oral anticoagulation therapy)